Living Microbial Drug Factory BioForge Receives FDA Approval: Gut-Resident Bacteria Produce Insulin In Vivo

Living Microbial Drug Factory BioForge Receives FDA Approval: Gut-Resident Bacteria Produce Insulin In Vivo

Biopharmaceutical company Synlogic today announced that its living microbial drug factory BioForge (SYN-2028) has received FDA approval as an adjunctive treatment for Type 1 diabetes. BioForge uses orally administered genetically engineered E. coli Nissle 1917 to continuously produce proinsulin in the patient's gut, which is absorbed through the intestinal wall and converted to active insulin.

Synlogic CEO Aoife Brennan stated: "BioForge represents an entirely new drug delivery paradigm—medications no longer require daily injections but are continuously produced by a 'living factory' resident in the body. This fundamentally transforms the treatment experience for chronic disease patients."

Phase III clinical trial data showed that Type 1 diabetes patients using BioForge experienced an average 80% reduction in daily insulin injections, with HbA1c blood sugar control comparable to the conventional treatment group. The most common adverse event was mild gastrointestinal discomfort (12% incidence), with no serious adverse events reported.

BioForge is priced at $2,800 per month and has been included in the formularies of Express Scripts and CVS Caremark. Synlogic indicated it is developing next-generation BioForge products for Crohn's disease, phenylketonuria, and hyperuricemia.

However, the safety of releasing genetically engineered microorganisms into the human gut raises long-term concerns. MIT synthetic biologist Jim Collins noted: "The evolutionary trajectory of engineered bacteria inside the human body is difficult to fully predict. We need long-term monitoring mechanisms to ensure engineered strains don't acquire unexpected competitive advantages or horizontal gene transfer capabilities."